Presentations by Program

Human PK and Dose Projection of ETX2514 / Sulbactam Combination for Use in the Treatment of Infections Caused by Acinetobacter baumannii

John O’Donnell, ID Week 2016

Sulbactam Combined with the Novel β–lactamase Inhibitor ETX2514 for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections

Alita Miller, ID Week 2016

A Phase II Trial of Single-Dose Oral ETX0914 (AZD0914) for Treatment of Uncomplicated Urogenital Gonorrhea

Ken Lawrence, ASM Microbe 2016

Addressing the Evolving Challenge of β-lactamase Mediated Antimicrobial Resistance: ETX2514, a Next-generation BLI with Potent, Broad Spectrum Activity Against Class A, C & D Enzymes

Ruben Tommasi, ASM Microbe 2016

In Vitro and In Vivo Efficacy of the Novel β-lactamase Inhibitor ETX2514 Combined with Sulbactam Against Multidrug Resistant Acinetobacter baumannii

John O’Donnell, ASM Microbe 2016

ETX2514, a Novel, Rationally Designed Inhibitor of Class A, C and D β–lactamases, for the Treatment of Gram-negative Infections

Adam Shapiro, ASM Microbe 2016

Challenges and Opportunities in Drug Discovery

Alita Miller, Boston Area Antimicrobial Research Network 2016

Improving our Understanding of Porin Permeability in Gram-negative Bacteria

Thomas Durand-Reville, Applied Pharmaceutical Chemistry Meeting 2016

Improving our Understanding of Porin Permeability in Gram-negative Bacteria

Thomas Durand-Reville, American Chemical Society Meeting 2016

Small Molecule Inhibitors of Gram-negative Lipoprotein Trafficking

Sarah McLeod, Gordon Research Conference on New Approaches to Antibacterial Research & Development 2016